Table S1.

Characterization of patients

Patient number	Age	Histology	Stage	Fagotti score	CA125 before NLHIPEC	CA125 after NLHIPEC	CA125 after the 3rd NACT	CA125 after IDS	Surgical complexity score groups	R0 resection	Recurrence after primary treatment (recurrent site, time of recurrence)	Treatment of recurrence	Patient status
1	65	Serous	IIIC	10	194	49	10	7	Intermediate	Yes	No	——	NED (11 moths)
2	68	Serous	IIIC	12	803	385	43	33	Intermediate	Yes	No	——	NED (15 moths)
3	66	Serous	IIIC	8	333	61	12	13	Low	No	No	——	NED (9 months)
4	70	Serous	IV	8	989	508	135	81	Intermediate	Yes	Yes (solitary paraaortic lymph nodes; 13 months)	SCS+chemothrapy (paclitaxel+caboplatin)	NED (19 months)
5	62	Serous	IV	8	3160	1947	344	32	Intermediate	No	No	——	NED (16 months)
6	46	Serous	IIIC	8	1714	343	166	55	High	Yes	No	——	NED (16 months)
7	38	Serous	IIIC	10	1039	114	14	14	Intermediate	No	No	——	NED (21 months)
8	32	Serous	IV	8	6536	1187	40	8	Intermediate	No	Yes (solitary pelvic peritoneum, liver; 16 months)	SCS+chemothrapy (paclitaxel+caboplatin)	NED (26 months)
9	53	Clear cell	IV	8	1220	606	19	19	Low	No	Yes (extensive intraperitoneal dissemination; 9 months)	Chemothrapy (irinotecan+caboplatin)	Stable disease
10	76	Serous	IIIC	12	1669	48	14	20	Intermediate	No	Yes (pelvic peritoneum, multiple lung lesions; 14 months)	Chemothrapy (paclitaxel+caboplatin) followed by Olaparib	Partial response (24 months)
11	62	Serous	IV	10	720	252	21	7	low	No	No	——	NED (13 months)
12	57	Serous	IIIC	8	3330	1414	240	59	High	No	No	——	NED (10 months)
13	32	Serous	IIIC	8	670	133	56	21	Intermediate	Yes	Yes (pelvic peritoneum, lung; 11 months)	Chemothrapy (paclitaxel+caboplatin)	Complete response (26 months)
14	69	Serous	IIIC	8	766	101	66	15	Intermediate	No	Yes (extensive intraperitoneal dissemination; 18 months)	Chemothrapy (paclitaxel+caboplatin)	Complete response (23 months)

Abbreviatios: NLHIPEC, neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy; NED, no evidence of disease; SCS, secondary cytoreductive surgery.